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Editorial
CF or not CF? That is the question
At many CF conferences there are case presentations,
discussion groups, or even whole sessions devoted to the
difficulties of categorising patients with some atypical
(and usually relatively mild) features of cystic fibrosis
who do not meet standard diagnostic criteria. They usu-
ally have at least one CFTR mutation. What diagnosis
shall we give? Sometimes, the patient or family want a
CF diagnosis to be made, sometimes not. Why do we
have so much difficulty giving a firm, clear answer to
the question?
For the great majority of patients, the old ‘gold stan-
dard’ sweat test criteria serve us well. The problem is
that the sweat test often fails us just when we need it
most. The group of atypical patients includes some who
have genuinely borderline results, and repeating the
sweat test several times confuses the clinician, when
some results may be just above or below our cut-off
level for normality. We than tend to select the results
which best fit our clinical impression and ignore the
others.
Twenty years ago, before the CFTR gene was discov-
ered, we delayed making a diagnosis in these patients in
the expectation that when the gene was found all would
become clear. On the contrary, it has made things more
difficult. With over 1000 mutations described, some of
which are apparently innocuous, the mere identification
of a mutation, or even two, does not of itself make the
diagnosis of cystic fibrosis (although in the case of
asymptomatic infants detected by neonatal screening,
finding two ‘severe’ mutations allows the prediction that
clinical features of CF will sooner or later emerge, prob-
ably sooner). However, the question remains whether a
given young adult with mild clinical features, an equiv-
ocal sweat test and a single ‘severe’ mutation (such as
F508del), either alone or in combination with a ‘mild’
mutation (such as R117H, in its 7T or 9T version), or
with 5T variant, should be diagnosed as having CF. The
decision remains a clinical one.
Several factors make us reluctant to use the CF diag-
nostic label too freely. The general public (in populations
of European descent) are now much more aware of CF
than they used to be. They have heard about the chronic
lung disease, transplants, and anticipated breakthroughs
in treatment. They know that it is a genetic problem, but
often have a poor understanding of genetic principles.
But they know that CF is a severe, life-shortening dis-
ease, to be feared.
Giving a CF diagnosis to this partly educated public
implies a burdensome program of daily treatment and a
prognosis, which may not be appropriate for the atypical
patient with mild disease. It also produces a disturbance
in the dynamics of the extended family (and careful
counselling of close and more distant relatives may be
requested, and required in any case). Furthermore, there
are issues of employment, insurance, fertility and per-
sonal relationships to be addressed.
The accessibility of information about CF via the
Internet has resulted in patients or families often learning
correct and incorrect facts about the disease, and its man-
agement, sooner than their medical advisers have antic-
ipated. They may suspect that the doctors are not giving
them a true picture.
This is not an argument for withholding or delaying
the diagnosis of CF, but rather one for widening our
diagnostic options and vocabulary by calling those indi-
viduals with mild, atypical disease (and probably a much
better than average prognosis) something other than
‘classical’ CF. The patient, the family, the health care
professionals, employees and insurance companies need
to recognise that the condition affecting these people
does not have the same implications for health, treat-
ment, employment and life expectancy as the stereotype
of CF, which they may have seen on their computer ter-
minal, medical textbook or television screens.
It was with these considerations in mind that a joint
WHOyICFMAyECFSyECFTN workshop looked at the
current classification in the International Classification
of Diseases 10th edition (ICD10) and found it wanting.
A new, broader and more flexible classification was pro-
posed, which it is hoped will find its way into the next
edition (ICD11).
In addition, as we expand our knowledge of condi-
tions which are clearly not CF, but in which CFTR muta-
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tions are common and probably have at least a
contribution, the workshop proposed that these diseases
(such as CBAVD and some cases of recurrent pancrea-
titis) should be classified along with CF in the same
section of ICD 11, if at least one mutation has been
identified. Further, for the first time it provides a code
for neonatal hypertrypsinogenaemia where there has not
been other evidence of CF, allowing those babies to be
recorded and perhaps reviewed. The problem of whether,
or how, to inform the parents of CF carriers that they
have been detected by the screening test, remains: and
it was not part of the workshop’s brief to resolve this
dilemma, only to provide an appropriate diagnostic code
to be used or not, according to local policy.
The Working Group recommendations are reprinted
on pages 5 to 8 by kind permission of the World Health
Organisation.
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